{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HD+Fluzone+Vaccine&page=2",
    "query": {
      "intervention": "HD Fluzone Vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HD+Fluzone+Vaccine&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HD+Fluzone+Vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T05:55:05.014Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01205581",
      "title": "Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fluzone High Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone Standard Dose Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 85,
      "start_date": "2010-09",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205581"
    },
    {
      "nct_id": "NCT05947071",
      "title": "High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunization; Infection",
        "Transplantation Infection",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 312,
      "start_date": "2024-09-26",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 10,
      "location_summary": "Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05947071"
    },
    {
      "nct_id": "NCT04622592",
      "title": "Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Instramuscular vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medicago",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 209,
      "start_date": "2020-11-02",
      "completion_date": "2022-04-26",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 14,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04622592"
    },
    {
      "nct_id": "NCT06431607",
      "title": "A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "F2G22B/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2H23D/DL001Z-NH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2H23B/DL001Z-NH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2H23H/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FDQ23A-NH (Flu D-QIV)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "GSK5800544A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flu D-TIV",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "F2H23A/DL001Z-NH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2H23G/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone HD Quadrivalent",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fluzone HD",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 845,
      "start_date": "2024-05-23",
      "completion_date": "2025-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 18,
      "location_summary": "Hialeah, Florida • Miami, Florida • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Valparaiso",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06431607"
    },
    {
      "nct_id": "NCT06641180",
      "title": "Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "High-Dose trivalent influenza vaccine (Split virion, Inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard-dose trivalent influenza vaccine (Split virion, Inactivated)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 1180,
      "start_date": "2024-11-04",
      "completion_date": "2025-06-24",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 20,
      "location_summary": "Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06641180"
    },
    {
      "nct_id": "NCT03698279",
      "title": "Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 665,
      "start_date": "2018-10-09",
      "completion_date": "2019-10-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 13,
      "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "El Dorado",
          "state": "Kansas"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03698279"
    },
    {
      "nct_id": "NCT03293498",
      "title": "Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "NanoFlu",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone HD - Day 0",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone HD - Day 21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline - Day 21",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2017-09-18",
      "completion_date": "2018-10-29",
      "has_results": true,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 3,
      "location_summary": "Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Rocky Mount",
          "state": "North Carolina"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03293498"
    },
    {
      "nct_id": "NCT02872311",
      "title": "Open-Label Influenza Vaccine Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immune Response"
      ],
      "interventions": [
        {
          "name": "High Dose Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adjuvanted Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Marshfield Clinic Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "65 Years to 74 Years"
      },
      "enrollment_count": 179,
      "start_date": "2016-09",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 1,
      "location_summary": "Marshfield, Wisconsin",
      "locations": [
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02872311"
    },
    {
      "nct_id": "NCT04484532",
      "title": "Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2017-10-17",
      "completion_date": "2022-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484532"
    },
    {
      "nct_id": "NCT07300085",
      "title": "A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Fluzone® High-Dose (HD) influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-1406 Injection",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 710,
      "start_date": "2025-11-08",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-01T05:55:05.014Z",
      "location_count": 4,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07300085"
    }
  ]
}